AzTrials
AzTrials

Patients With FracturesPhase 4OsteogenonNCT07210281

Osteogenon in Orthopedics and Traumatology

A Phase 4 study testing received an ossein-hydroxyapatite complex in people with Patients With Fractures, run by University of Opole at 1 site in Poland.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The aim of this study was to evaluate the supportive effect of the ossein-hydroxyapatite complex in fracture healing. The investigators hypothesized that the ossein-hydroxyapatite complex would positively impact fracture healing outcomes.The assessment covers clinical, radiological and biomechanical parameters. Read more about this study

Who is it for?
Ages 18 to 85 years
Conditions the study is for
Patients With Fractures
What is being tested?
received an ossein-hydroxyapatite complex
Type of treatment
Pill or oral medicine
Could I receive a placebo?
No, everyone receives an active treatment
How many people
150 participants
Where
1 sitePoland
Study dates
1 Nov 2024to 30 Dec 2027
Phase
Phase 4
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 85 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • no contraindications to taking Osteogenon
  • a follow-up period of more than 3 months after treatment completion
  • complete medical and radiological records
  • a written informed consent
  • not taking any other medications that could affect bone tissue remodeling
  • not taking other medications that interact with Osteogenon
  • no other limb pathologies (inflammatory or neurogenic)
  • absence of comorbidities that could affect bone union

Who cannot join

  • age under 18 years or over 85 years
  • hypersensitivity to the active ingredient or to any of the excipients
  • severe renal failure and dialysis therapy
  • hypercalcemia
  • hypercalciuria
  • calcium-based kidney stones or tissue calcifications
Show all 16Show fewer
  • a follow-up period shorter than 3 months after treatment completion
  • a lack of informed consent
  • a lack of cooperation with the patient
  • absent or incomplete medical and radiological records
  • taking medications that could affect bone tissue remodeling
  • taking medications that may interact with Osteogenon (e.g. thiazide diuretics)
  • metabolic disorders
  • post-traumatic skeletal deformities
  • neuromuscular disorders
  • post-inflammatory deformities

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Poland1 site, 1 recruiting
  • University Clinical Hospital in Opole

    Opole, Opole Voivodeship, 46-020

    Piotr Morasiewicz, PROF, +48504549666, piotr.morasiewicz@uni.opole.pl

    Monika Zaborska, +48692706595, zaborska.monika.pl@gmail.com

    Recruiting

Other trials in Poland

About this study

Official title: The Use of Ossein-hydroxyapatite Complex as an Adjunctive Treatment in Orthopedics and Traumatology

The aim of this study was to evaluate the supportive effect of the ossein-hydroxyapatite complex in fracture healing. The investigators hypothesized that the ossein-hydroxyapatite complex would positively impact fracture healing outcomes.The assessment covers clinical, radiological and biomechanical parameters.

Read the detailed description

The role of ossein-hydroxyapatite complex in fracture healing requires further research.

The aim of the study was to evaluate the effect of ossein-hydroxyapatite complex (Osteogenon) as an adjunctive treatment on the outcome of conservative and surgical fractures treatment via comprehensive clinical, radiological and biomechanical assessments. The investigators aimed to reject the null hypothesis of the absence of beneficial effect of ossein-hydroxyapatite complex on fractures treatment outcomes. This would fill the existing gap in the scientific literature and enable a more widespread use of Osteogenon in the treatment of fractures in many trauma centers.

Patients in the study group with fractures received an ossein-hydroxyapatite complex (830 milligram [mg] of ossein-and-hydroxyapatite complex, with 444 mg of hydroxyapatite, equivalent to 178 mg of calcium and 82 mg of phosphorus) throughout the entire period following fracture healing. The tablets were taken orally, one tablet twice daily.

The drug Osteogenon used in our study had been approved for fracture treatment. The study was conducted in accordance with the Declaration of Helsinki and all applicable laws and regulations. All patients had provided their written informed consent and were informed of a voluntary nature of their participation in this study.

Patients participating in the study, both in the study and control groups, had to meet the inclusion criteria. The randomization method used was to evenly recruit the study and control groups as patients who met the inclusion criteria were recruited. Randomization took into account the equal distribution of gender and age in both groups.

Patients from both the experimental and control groups received the same recommendations regarding rehabilitation and had the same clinical and radiological follow-up protocol.

The following clinical, biomechanical and radiological parameters were assessed in the study: the period of immobilization, rate of bone union, analgesic use at the beginning of treatment, analgesic use during the follow-up, time to achieving pain relief, pain in 100 millimeter [mm] Visual Analogue Scale (VAS), number of patients declaring pain relief, rate of complications, time to resuming normal physical activity, grip strength, muscle strength during joint movement.

The period of immobilization was defined as the total number of days during which cast immobilization was maintained. The time to resuming normal physical activity was expressed in days and defined as the period from injury to return to work or school and normal everyday activities.

The rate of bone union was determined based on the percentage of patients who achieved clinical and radiological criteria of bone union. The radiological criteria of bone union were the presence of a minimum of 3 out of 4 consolidated cortical bone layers or trabecular transition between bone fragments on X-rays in 2 views. Clinical bone union was defined as the lack of pathological mobility, pain, or deformity during attempts to perform movements in the wrist area at the fracture site. Nonunion was defined as failure to meet the above criteria for 6 months after the fracture .

The investigators also assessed the number of patients on any analgesics (paracetamol, ibuprofen, non-steroidal anti-inflammatory drugs, tramadol) at the beginning of treatment and at the final follow-up. During regular follow-up visits, patients were asked about their pain intensity using the NRS (Numerical Rating Scale). A period of discontinuation of any pain medication was equivalent to a patient rating their pain level as 0 on the NRS. Time to achieving pain relief was expressed in days and defined as the period from the beginning to end of taking any analgesic drugs.

Complications were assessed based on medical and radiological records. The evaluated complications included nonunion, delayed bone union, fragment displacement, persistent pain, persistent swelling, limited range of motion, vascular damage, nerve damage, the need for revision surgery or repeated reduction and immobilization.

Being tested
received an ossein-hydroxyapatite complex
Keywords
fractures, Osteogenon, ossein-hydroxyapatite complex, distal radius fractures, lower leg fracture, proximal humerus fractures
Medical subject headings
Fractures, Bone, Wrist Fractures

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • received an ossein-hydroxyapatite complexDrug

    Patients in the study group with fractures received an ossein-hydroxyapatite complex (830 mg of ossein-and-hydroxyapatite complex, with 444 mg of hydroxyapatite, equivalent to 178 mg of calcium and 82 mg of phosphorus) throughout the entire period following fracture healing. The tablets were taken orally, one tablet twice daily.

Study groups in NCT07210281
Study groupRoleWhat they receive
OsteogenonExperimentalreceived an ossein-hydroxyapatite complex
Receives: Drug: received an ossein-hydroxyapatite complex
ControlNo interventiondid not receive an ossein-hydroxyapatite complex

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. period of bone union

    assessed by data linkage to medical and radiological records

    Measured: at 6 months after randomisation

  2. Achieving bone union

    assessed by data linkage to medical and radiological records

    Measured: at 6 months after randomisation

Secondary outcomes (1)
  1. pain assessment

    100mm Visual Analogue Scale (VAS)

    • 0 mm indicates "no pain"
    • 100 mm indicates "worst imaginable pain"
    • Higher scores on the VAS indicate a worse outcome (greater pain intensity).

    Measured: at 6 months after randomisation

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted7 Oct 2025
  2. Study start1 Nov 2024
  3. Primary completion2 Feb 2027 (estimated)
  4. Study completion30 Dec 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Single group
Masking
None (open label)
Enrolment
150 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07210281
Sponsor's protocol ID
P-2025-003
Other IDs
P-2025-004
Acronym
Osteogenon
Status last verified
Nov 2025
First submitted
29 Sep 2025
Last updated
28 Nov 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: The data collected during our study are our own efforts and will be used to prepare our publications. Other authors are encouraged to conduct their own research.

Publications

  • Morasiewicz P, Zaborska M, Sobczak M, Tomczyk L, Leyko P, Bobinski A, Kochanska-Bieri J, Pili D, Kazubski K. The Use of Osteogenon as an Adjunctive Treatment in Lower Leg Fractures. Pharmaceuticals (Basel). 2024 Nov 14;17(11):1531. doi: 10.3390/ph17111531.

    PubMed 39598441
  • Morasiewicz P, Zaborska M, Sobczak M, Tomczyk L, Pili D, Kazubski K, Leyko P. The Use of Ossein-Hydroxyapatite Complex in Conjunction with the Ilizarov Method in the Treatment of Tibial Nonunion. J Clin Med. 2025 May 12;14(10):3353. doi: 10.3390/jcm14103353.

    PubMed 40429349

Questions about this trial

What is this clinical trial studying?

A Phase 4 study testing received an ossein-hydroxyapatite complex in people with Patients With Fractures, run by University of Opole at 1 site in Poland.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 8 inclusion and 16 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 28 Nov 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Poland. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this phase mean?

Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Piotr Morasiewicz, PROF (+48504549666, piotr.morasiewicz@uni.opole.pl), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

period of bone union (time frame: at 6 months after randomisation). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT07210281, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Nov 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in